朱海珍， 男，群众，1969年04月生，医学博士，教授，博士生导师，湖南大学生物学院分子医学系主任，湖南大学生物学院学术委员会主任，2009年教育部新世纪优秀人才支持计划获得者
。学习经历1990年毕业于，获得医学学士学位；1997年毕业于，获得医学硕士学位；2000年毕业于，获得医学博士学位。工作经历1990-1994年 助教；2000-2005年在美国医学院病理学、免疫学和实验医学系从事博士后研究工作；2005-2009年任美国医学院病理学、免疫学和实验医学系的Assistant Scientist；自2008年起任教授；2010年起兼任（附属肿瘤医院）教授。
主讲生物学院本科生 《药理学》课程。主讲生物学院研究生 《专业英语》课程。主要从事分子病毒学与免疫学、肿瘤分子生物学领域的教学和科研工作。具体研究内容包括病毒与宿主的相互作用、肿瘤细胞信号传导及耐药机制、病毒及肿瘤细胞的免疫逃逸机制，以及消化道肿瘤和肝炎新型靶向药物、疫苗的研发。
多年来一直从事消化道肿瘤和肝炎的发病机制、耐药机制以及药物与疫苗研发工作。主持承担国家科技重大专项、国家自然科学基金等多项科研项目，共计科研经费1000余万元。在PNAS、Gastroenterology、Hepatology、J Virology等国际顶级学术刊物上发表70余篇论文，其中多篇论文被撰写述评和作为研究亮点报道。多次应邀在病毒性肝炎和肝病国际国内学术会议上作特邀报告。获得1项美国发明专利并授权，申请了另一项美国和欧盟发明专利，申请了多项国家发明专利，其中5项已获授权。获得湖南省科技进步奖1项。
1、“核酸适体在丙型病毒性肝炎早期诊断和靶向治疗中的应用基础研究”（2009ZX10004-312） “艾滋病和病毒性肝炎等重大传染病防治” 768万元。2、“丙型病毒性肝炎发病机制探讨” 教育部新世纪优秀人才支持计划 50万元。3、“肝炎病毒感染小鼠模型的构建” 湖南省科研条件创新专项 5万元。1. Eksioglu E, Bess J, , Xu Y, Dong H, Elyar J, Nelson DR, Liu C. Hepatitis C virus modulates human monocyte-derived dendritic cells.  2010; 17:757-769 (IF:3.348)。2. Eksioglu EA, Bess J, Jones G, Dettloff J, Dangmeon P, Dong HJ, , Firpi R, Xu Y, Nelson DR, Liu C. Characterization of anti-HCV antibodies in IL-10 treated patients.  2010;23:359-368 (IF:1.779)。3. , Elyar J, Foss R, Hemming A, Hall E, Lecluyse EL, Liu C. Primary human hepatocyte culture for HCV study. , 2009 510:373-382。4. Kenworthy R, Lambert D, Yang F, Wang N, Chen Z,, Zhu F, Liu C, Li K, Tang H. Short-hairpin RNAs delivered by lentiviral vector transduction trigger RIG-I-mediated IFN activation. .2009;37:6587-6599 (IF: 7.48)。5. Wu H, , Zhuang J, Liu C, Cao YC. Water-soluble nanocrystals through dual-interaction ligands. . 2008; 47:3730-34. (IF: 11.829)Butler SL, Dong H, Cardona D, Jia M, Zheng R, , Crawford JM, Liu C. The antigen for Hep Par 1 antibody is the urea cycle enzyme carbamoyl phosphate synthetase 1.  2008; 88:78-88. (IF: 4.602)。6. , Dong H, Eksioglu E, Hemming A, Cao M, Crawford CM, Nelson DR, Liu C. Hepatitis C virus triggers cell death through innate intracellular antiviral defense system.  2007; 133:1649-1659 (IF: 12.899)。7. Liu C, , Subramanian MG, Moore PA, Xu Y, Nelson DR. Anti-hepatitis C virus activity of albinterferon alfa-2b in cell culture. . 2007; 37:941-947. (IF: 1.540)。8. Cao M, Cabrera R, Xu Y, Firpi R, , Liu C, Nelson DR. Hepatocellular carcinoma cell supernatants increase expansion and function of CD4(+)CD25(+) regulatory T cells. . 2007, 87:582-590. (IF: 4.602)。9. Firpi RJ, , Morelli G, Abdelmalek MF, Reed AI, Liu C, Nelson DR. Cyclosporine suppresses hepatitis C virus in vitro and increase the chance of sustained virological response after liver transplantation.  2006, 12:51-57 (IF: 4.085)。10. , Butera M, Nelson DR and Liu C. Novel type I Interferon IL-28A suppresses hepatitis C viral RNA replication.  2005, 2:80 (IF: 2.435)。11. , Nelson DR, Crawford JM and Liu C. Defective JAK-STAT activation in host cells confers hepatitis C viral interferon-alpha resistance.  2005, 25(9): 528-539 (IF: 1.627)。12. Rufforny I, Wilkinson EJ, Liu C, , Buteral M, Massoll NA. Human papillomavirus infection and p16 (INK4a) protein expression in vulvar intraepithelial neoplasia and invasive squamous cell carcinoma. . 2005, 9(2):108-113。13. , Shang X, Terada N, Liu C. STAT3 induces anti-hepatitis C viral activity in liver cells.  2004; 324:518-528 (IF: 2.55)。14. Shang XZ, , Lin K, Tu Z, Chen J, Nelson DR and Liu C. Stabilized b-catenin promotes hepatocyte proliferation and inhibits TNFa-induced apoptosis.  2004; 84:332-341 (IF: 4.602)。15. Nelson DR, Tu Z, Soldevila-Pico C, Abdelmalek M, , Xu YL, Cabrera R, Liu C and Davis G. Long-term interleukin10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. 2003; 38:859-868 (IF: 11.355)。16. *Liu C, , Tu Z, Xu YL and Nelson DR. CD8+ T cell interaction with HCV replicon cells: evidence for both cytokine- and cell—mediated antiviral activity. 2003; 37:1335-1342 (IF:11.355)17. , Zhao H, Collins CD, Eckerrode SE, Ruan Q, Mcindoe RA, Crawford JM, Nelson DR, She JX and Liu C. Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line.  2003; 37:1180-1188  (IF: 11.355)。18.  and Liu C. Interleukin-1 inhibit hepatitis C virus subgenomic RNA replication by activation of extracellular regulated kinase pathway.  2003; 77:5493-5498 (IF: 5.15)。19. , Ruan YB, Wu ZB and Zhang CM. Kupffer cell and apoptosis in experimental HCC.  2000; 6:405-407(IF:2.092)。20. , Ruan Y, Yang M, Wu Z, Zhang C. The influence of Kupffer cells on apoptosis in the experimental hepatocellular carcinoma 2000; 9:138-141。21. Staudacher C, Chiappa A, Zbar AP, Bertani E, Biella F, . Evalution of risk factors in the development of postoperative complications in patients undergoing liver resection for cancer.  2000; 52:123-129。22. , Ruan Y, Wu Z. The influence of Kupffer cells on the expression of apoptosis related genes in experimental hepatocellular carcinoma.  2000; 29:97-99。23. , Ruan Y, Yang M, Wu Z and Ivankovic S. The role of Kupffer cells in experimental hepatocarcinogenesis: a microscopic, light and electron microscopic observation.  1998; 27:420-422, 430。24. , Ruan Y, Wu Z. The influence of Kupffer cells on experimental hepatocarcinogenesis.  1998; 27: 102-104。1., Elyar J, Foss R, Hemming A, Hall E, Lecluyse EL, Liu C. Chapter 28 Primary human hepatocyte culture for HCV study.  Vol 510, p373-382. The Humana Press, 2009。Human liver cancer cell line. International Application No. PCT/US2007/ 006722.
 白求恩医科大学同济医科大学华中科技大学同济医学院同济医科大学佛罗里达大学佛罗里达大学湖南大学生物学院湖南省肿瘤医院中南大学湘雅医学院   国家科技重大专项 